SE9904412D0 - Comminuted form - Google Patents

Comminuted form

Info

Publication number
SE9904412D0
SE9904412D0 SE9904412A SE9904412A SE9904412D0 SE 9904412 D0 SE9904412 D0 SE 9904412D0 SE 9904412 A SE9904412 A SE 9904412A SE 9904412 A SE9904412 A SE 9904412A SE 9904412 D0 SE9904412 D0 SE 9904412D0
Authority
SE
Sweden
Prior art keywords
compound
pharmaceutically acceptable
particle size
acceptable salt
reduced particle
Prior art date
Application number
SE9904412A
Other languages
Swedish (sv)
Inventor
Kristina Roos
Agneta Haellgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9904412A priority Critical patent/SE9904412D0/en
Publication of SE9904412D0 publication Critical patent/SE9904412D0/en
Priority to PCT/SE2000/002380 priority patent/WO2001040166A1/en
Priority to AU20347/01A priority patent/AU2034701A/en
Priority to CO00091394A priority patent/CO5271723A1/en
Priority to ARP000106385A priority patent/AR026705A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Abstract

The present invention relates to a reduced particle size form of the compound 3-{4-[2-(4-<i>tert</i>-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid, as shown in formula (I), or a pharmaceutically acceptable salt thereof or a solvate of either thereof. The invention also concerns methods of treating one or more conditions associated with Insulin Resistance Syndrome using the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in one or more of said conditions. The invention further concerns pharmaceutical compositions containing the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient, as well as processes for the manufacture of the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof.
SE9904412A 1999-12-03 1999-12-03 Comminuted form SE9904412D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE9904412A SE9904412D0 (en) 1999-12-03 1999-12-03 Comminuted form
PCT/SE2000/002380 WO2001040166A1 (en) 1999-12-03 2000-11-29 Comminuted form of 3-{4-[2-(4-tert-butoxycarbonylaminophenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic
AU20347/01A AU2034701A (en) 1999-12-03 2000-11-29 Comminuted form of 3-(4-(2-(4-tert-butoxycarbonylaminophenyl)ethoxy)phenyl)-(s) 2-ethoxy propanoic
CO00091394A CO5271723A1 (en) 1999-12-03 2000-11-29 SHREDDED FORM
ARP000106385A AR026705A1 (en) 1999-12-03 2000-12-01 SHREDDED FORM

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904412A SE9904412D0 (en) 1999-12-03 1999-12-03 Comminuted form

Publications (1)

Publication Number Publication Date
SE9904412D0 true SE9904412D0 (en) 1999-12-03

Family

ID=20417977

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904412A SE9904412D0 (en) 1999-12-03 1999-12-03 Comminuted form

Country Status (5)

Country Link
AR (1) AR026705A1 (en)
AU (1) AU2034701A (en)
CO (1) CO5271723A1 (en)
SE (1) SE9904412D0 (en)
WO (1) WO2001040166A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1198699A (en) 1997-10-27 1999-04-23 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
RU2235094C2 (en) 1997-10-27 2004-08-27 Др. Редди`З Лабораториз Лимитед Beta-aryl-alpha-hydroxy-substituted alkylcarboxylic acids, methods for their preparing, intermediate compounds, methods for their preparing, pharmaceutical composition, methods for treatment or prophylaxis of diseases based on new compounds
HUP0101110A3 (en) 1997-10-27 2002-06-28 Reddys Lab Ltd Dr Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
JP2002528535A (en) 1998-10-29 2002-09-03 ドクター・レディーズ・リサーチ・ファウンデーション An improved method for producing new antidiabetic agents
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA26634A1 (en) * 1998-06-04 2004-12-20 Astra Ab NOVEL 3-ARYL PROPIONIC ACID DERIVATIVES AND THE LIKE
SE9801990D0 (en) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs

Also Published As

Publication number Publication date
AU2034701A (en) 2001-06-12
WO2001040166A1 (en) 2001-06-07
AR026705A1 (en) 2003-02-26
CO5271723A1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
SE9904413D0 (en) Comminuted form
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
DE60107820D1 (en) NEW USE OF PHENYLHETEROALKYLAMINE DERIVATIVES
CY1107850T1 (en) THIADIAZYLOPIPERAZINE PRODUCT WITH USE IN APTROPIC OR IN ACTION AGAINST ALGUES
MXPA04002338A (en) Carbazole derivatives and their use as npy5 receptor antagonists.
JO2282B1 (en) Oxazol derivatives
NO20066041L (en) Use of substituted quinoline derivatives for the treatment and drug-resistant mycobacterial diseases
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
MY144209A (en) Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MA27702A1 (en) PREPARATION OF STERILE AQUEOUS SUSPENSIONS COMPRISING MICRONIZED CRYSTALLINE ACTIVE INGREDIENTS INTENDED FOR INHALATION
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
RU2008129723A (en) CCR9 ACTIVITY INHIBITORS
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
BR0313407A (en) New use of benzothiazole derivatives
SE0302573D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
MY124727A (en) Tri-substituted phenyl derivatives and analogues.
SE9904412D0 (en) Comminuted form
EA200200489A1 (en) NEW COMPOUNDS OF BENZOTHIADIAZINE, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
SE0302572D0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof